French judge charges boss of breast implant firm
January 27, 2012 by Anne Beade in OtherA French judge on Friday charged the founder of the breast implant company at the heart of a global health scare with "involuntary injuries", his lawyer said.
More than 400,000 women around the world are believed to have received implants made by Poly Implant Prothese (PIP), which shut down in 2010 after it was revealed to have been using substandard, industrial-grade silicone gel.
Its founder Jean-Claude Mas, 72, was arrested Thursday in the southern city of Marseille on the orders of an investigating judge.
His lawyer, Yves Haddad, said he was later charged with "involuntary injuries" during a late-night hearing and released on bail pending further investigation.
Mas was grilled by investigators and answered hundreds of questions, Haddad said, describing his client as "very cooperative", outlining the responsibilities of all company officials and his links with suppliers.
Prosecutors said police had also arrested Claude Couty, another former executive at the now-defunct PIP, in southern France.
Fears over PIP implants spread globally late last year after French health authorities advised 30,000 women to have theirs removed because of an increased risk of rupture.
Between 400,000 and 500,000 women in 65 countries are believed to have received implants from PIP, once the world's largest silicone implant producers.
A number of countries, including Germany and the Czech Republic, followed France in recommending that the implants be removed as a precaution but Britain has said it will not follow suit.
Thirteen countries in Europe and Latin America have also urged women to have a checkup.
French officials have said that cancer, including 16 cases of breast cancer, had been detected in 20 French women with the implants, but have insisted there is no proven link.
Mas was arrested at his partner's home in the south of France. Dallest said police searched the residence, in the town of Six-Fours-les-Plages, for evidence.
During earlier questioning, Mas confirmed the implants were made with a non-authorised silicone gel but rejected any suggestion that they posed a health risk.
"I knew that the gel wasn't approved, but I did it knowingly, because the PIP gel was cheaper ... and of much better quality," Mas said, according to the minutes of a police interview conducted in October, and seen by AFP.
Philippe Courtois, a lawyer representing women who received the PIP implants, said he was encouraged by Mas' arrest but did not expect his story to change.
"Considering the outrageous statements he has made in regards to all the victims, we do not expect very much from this hearing," Courtois said.
Representatives of two groups campaigning for women who received the implants were to appear before the investigating judge on Friday.
Along with the manslaughter investigation, prosecutors in Marseille have already concluded an aggravated fraud case in the implant scandal that is expected to be brought to court by the end of the year.
Marseille prosecutors have received more than 2,500 complaints in the case, which has sparked calls for wider European regulation and monitoring of medical devices such as breast implants.
Mas, a former travelling salesman who got his start in the medical business by selling pharmaceuticals, founded PIP in 1991 to take advantage of the booming market for cosmetic implants.
He reportedly told investigators that he used fake business data to fool health inspectors.
The substandard gel was in 75 percent of PIP breast implants, saving the company about one million euros ($1.3 million) annually, according to an ex-company executive.
In May 2000 the US Food and Drug Administration warned PIP of "serious" quality control violations involving saline implants after an inspection of its French factory.
(c) 2012 AFP
-
Breast implant maker used non-approved gels: lawyer
Dec 27, 2011 |
not rated yet |
0
-
French police arrest boss of breast implant company
Jan 26, 2012 |
not rated yet |
0
-
Dutch women reimbursed for breast implant removals
Jan 26, 2012 |
not rated yet |
0
-
20 cancer cases in French women with PIP implants: agency
Dec 30, 2011 |
not rated yet |
0
-
Interpol seeks arrest of breast implant company founder
Dec 24, 2011 |
not rated yet |
0
-
Remembrance of things future: Long-term memory sets the stage for visual perception
Dec 28, 2011 |
3.6 / 5 (13) |
4
-
Beyond brain scanning: Simultaneous high-resolution 3D neural imaging and photostimulation
Nov 28, 2011 |
5 / 5 (8) |
2
-
The error-correcting brain: New insights into the neurobiology of adaptive behavior
Oct 27, 2011 |
4.9 / 5 (10) |
6
-
The brain on drugs: Defining the neural anatomy and physiology of morphine on dopamine neurons
Oct 04, 2011 |
4.8 / 5 (4) |
1
-
Now see this: Anti-inflammatory treatment reverses stroke-induced compromise in sensory learning
Sep 22, 2011 |
4 / 5 (9) |
2
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
Study: Virtual colonoscopy effective screening tool for adults over 65
Computed tomography (CT) colonography can be used as a primary screening tool for colorectal cancer in adults over the age of 65, according to a new study published online in the journal Radiology.
Other
4 minutes ago |
not rated yet |
0
ACGME announces plan to transform graduate medical education
The Accreditation Council for Graduate Medical Education (ACGME) today announced major changes in how the nation's medical residency programs will be accredited in the years ahead, putting in place an outcomes-based evaluation ...
Other
6 hours ago |
not rated yet |
0
Paying research volunteers raises ethical concerns, study concludes
(Garrison, NY) Researchers almost always offer money as an incentive for healthy volunteers to enroll in research studies, but does payment amount to coercion or undue inducement to participate in research? In the first national ...
Other
12 hours ago |
2 / 5 (1) |
0
Shifting the clinical teaching paradigm in undergraduate nursing education
To address the faculty shortage problem, schools of nursing are reexamining how they provide clinical education to undergraduate students to find ways to use faculty resources more efficiently so they can maintain student ...
Other
12 hours ago |
not rated yet |
0
Johnson & Johnson CEO to step down in April
(AP) -- Johnson & Johnson's longtime CEO Bill Weldon is stepping down as the health care giant's top executive after an embarrassing string of recalls of everything from Tylenol to Benadryl that has cost the company hundreds ...
Other
18 hours ago |
not rated yet |
0
CT colonography shown to be comparable to standard colonoscopy
Computerized tomographic (CT) colonography (CTC), also known as virtual colonoscopy, is comparable to standard colonoscopy in its ability to accurately detect cancer and precancerous polyps in people ages 65 and older, according ...
Mini molecules could help fight battle of aortic bulge
When aortic walls buckle, the body's main blood pipe forms an ever-growing bulge. To thwart a deadly rupture, a team of Stanford University School of Medicine researchers has found two tiny molecules that may be able to orchestrate ...
Research links circadian rhythms to sudden cardiac death
A fundamental discovery reported in the March 1st issue of the journal Nature, uncovers the first molecular evidence linking the body's natural circadian rhythms to sudden cardiac death (SCD). Ventricular arrhythmias, or abn ...
Analysis of mTOR shows how the protein works, how new generation of drugs may defeat it
Uncovering the network of genes regulated by a crucial molecule involved in cancer called mTOR, which controls protein production inside cells, researchers at the University of California, San Francisco (UCSF) have discovered ...
Phobia's effect on perception of feared object allows fear to persist
The more afraid a person is of a spider, the bigger that individual perceives the spider to be, new research suggests.
New melanoma drug Zelboraf nearly doubles survival in majority of patients
Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.